Literature DB >> 15994773

Equine infectious anemia virus Gag p9 function in early steps of virus infection and provirus production.

Sha Jin1, Chaoping Chen, Ronald C Montelaro.   

Abstract

We have previously reported that serial truncation of the Gag p9 protein of equine infectious anemia virus (EIAV) revealed a progressive loss in replication phenotypes in transfected cells, such that a proviral mutant (E32) expressing the N-terminal 31 amino acids of p9 produced infectious virus particles similarly to parental provirus, while a proviral mutant (K30) with two fewer amino acids produced replication-defective virus particles, despite containing apparently normal levels of processed Gag and Pol proteins (C. Chen, F. Li, and R. C. Montelaro, J. Virol. 75:9762-9760, 2001). Based on these observations, we sought in the current study to identify the precise defect in K30 virion infection of permissive equine dermal (ED) cells. The results of these experiments clearly demonstrated that K30 virions entered target ED cells and produced early (minus-strand strong-stop) and late (Gag) viral DNA products as efficiently as did the replication-competent E32 mutant and parental EIAV(UK) viruses. However, in contrast to the replication-competent E32 mutant and parental viruses, infection with K30 mutant virus failed to produce detectable two-long-terminal-repeat DNA circles, stable integrated provirus, virus-specific Gag mRNA expression, or intracellular viral protein expression. Taken together, these data demonstrate that the K30 mutant is defective in the ability to produce sufficient nuclear viral DNA to establish a productive infection in ED cells. Thus, these observations indicate for the first time that the EIAV Gag p9 protein performs a critical role in viral DNA production and processing to provirus during EIAV infection, in addition to its previously defined role in viral budding mediated by the p9 L domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994773      PMCID: PMC1168773          DOI: 10.1128/JVI.79.14.8793-8801.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells.

Authors:  Z Nie; D Bergeron; R A Subbramanian; X J Yao; F Checroune; N Rougeau; E A Cohen
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Identification of three major phosphorylation sites within HIV-1 capsid. Role of phosphorylation during the early steps of infection.

Authors:  C Cartier; P Sivard; C Tranchat; D Decimo; C Desgranges; V Boyer
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

3.  Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses.

Authors:  Sha Jin; Charles J Issel; Ronald C Montelaro
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

4.  Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle.

Authors:  B Yuan; X Li; S P Goff
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

5.  Specific incorporation of cyclophilin A into HIV-1 virions.

Authors:  E K Franke; H E Yuan; J Luban
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

6.  Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.

Authors:  C Lavallée; X J Yao; A Ladha; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 7.  Viral gene products and replication of the human immunodeficiency type 1 virus.

Authors:  C D Morrow; J Park; J K Wakefield
Journal:  Am J Physiol       Date:  1994-05

8.  2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo.

Authors:  C D Pauza; P Trivedi; T S McKechnie; D D Richman; F M Graziano
Journal:  Virology       Date:  1994-12       Impact factor: 3.616

9.  The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.

Authors:  U von Schwedler; R S Kornbluth; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

10.  Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome.

Authors:  B Allain; M Lapadat-Tapolsky; C Berlioz; J L Darlix
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  7 in total

1.  Porous membrane substrates offer better niches to enhance the Wnt signaling and promote human embryonic stem cell growth and differentiation.

Authors:  Sha Jin; Huantong Yao; Pantrika Krisanarungson; Andreas Haukas; Kaiming Ye
Journal:  Tissue Eng Part A       Date:  2012-04-18       Impact factor: 3.845

2.  Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Authors:  Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Fenglong Wang; Rongxian Shen; Jianhua Zhou
Journal:  Virus Genes       Date:  2011-01-08       Impact factor: 2.332

3.  Receptor-mediated entry by equine infectious anemia virus utilizes a pH-dependent endocytic pathway.

Authors:  Sha Jin; Baoshan Zhang; Ora A Weisz; Ronald C Montelaro
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.

Authors:  Han Lei; Sha Jin; Erik Karlsson; Stacey Schultz-Cherry; Kaiming Ye
Journal:  J Immunol Res       Date:  2016-12-19       Impact factor: 4.818

5.  Solution structure of the equine infectious anemia virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein.

Authors:  Alok Sharma; Karsten Bruns; René Röder; Peter Henklein; Jörg Votteler; Victor Wray; Ulrich Schubert
Journal:  BMC Struct Biol       Date:  2009-12-17

6.  A synthetic, xeno-free peptide surface for expansion and directed differentiation of human induced pluripotent stem cells.

Authors:  Sha Jin; Huantong Yao; Jennifer L Weber; Zara K Melkoumian; Kaiming Ye
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  Genetic Evolution during the development of an attenuated EIAV vaccine.

Authors:  Xue-Feng Wang; Yue-Zhi Lin; Qiang Li; Qiang Liu; Wei-Wei Zhao; Cheng Du; Jie Chen; Xiaojun Wang; Jian-Hua Zhou
Journal:  Retrovirology       Date:  2016-02-03       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.